Combining independent risk factors from multivariate analysis, including ROS1 gene mutations, KRAS gene mutations, tumor stage, and endocrine system disease history, a new Nomogram was constructed to predict the therapeutic efficacy of ICIs immunotherapy in PD-L1 positive patients. This evidence concerns the gene ROS1 and neoplasm.